Agreement with IRIS a ‘major breakthrough’ for DIAGNOS path to global commercialization

Did you know that doctors can study the retina of your eye and get an early reading on the condition of your arteries in your body? Going one step further a company has recently completed a successful pilot study for early stroke detection using their AI driven retina analysis technology and is now moving onto clinical trials. According to the World Health Organization, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled. Strokes cause 1 out of every 20 deaths and represent a cost of approximately US$34 billion per year in the United States.

The Company is DIAGNOS Inc. (TSXV: ADK | OTCQB: DGNOF) (“DIAGNOS”). DIAGNOS is a leader in artificial intelligence (AI) and healthcare technical services including algorithm development, data analysis, and image processing ever since 2001. DIAGNOS has developed an AI tele-ophthalmology platform known as CARA (Computer Assisted Retina Analysis) to examine patient’s retinas in the eye for the early detection of diseases such as diabetics, hypertension and other cardiovascular disease (including stroke). CARA integrates with existing equipment (hardware and software) making it suitable for existing practitioners. CARA uses AI algorithms to make standard retinal images sharper, clearer and easier to read. Effectively this means better early stage diagnosis of the various cardiovascular diseases mentioned above.

CARA is also a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia). DIAGNOS already operates in 16 countries, 131 screening sites, and has 222,034 patients under their care.

DIAGNOS has developed AI to help better diagnose cardiovascular disease in the retina of the eye

Source: Diagnos Inc. website

CARA will now undergo clinical trials to test its effectiveness in detecting patients at risk of stroke

Riadh Kobbi, Vice President Data Science at DIAGNOS, states:

“CARA-ST will be able to predict the viability of developing a stroke condition based on the micro circulation analysis of the retina image of the patient. DIAGNOS has been developing this technology for the last four years and because of the conditions brought on by the COVID-19 pandemic, we were able to expedite the final testing and development of our new application…..This year our new stroke management application will be field tested in multiple countries.”

The global rollout of CARA commercialization continues

Announced in March 2021, Óptica Central (in collaboration with Aselcom, DIAGNOS’ distributor) has begun pilot testing screening of patients using DIAGNOS’s CARA Telemedicine technology. Óptica Central is the third largest optical retailer in Costa Rica. Óptica Central offers optics and optometry services. Their CEO, Jefrey Salas, stated:

“Óptica Central…..are pleased to start screening the population across our optical stores by providing DIAGNOS’ proven AI solution for early detection of eye illnesses, such as Diabetic Retinopathy, as well as preventing blindness caused by diabetes. There is no doubt that DIAGNOS’ experience in Costa Rica, and in other Latin American countries, has been at the forefront in proving its service with their remarkable technology.”

Announced in April, 2021, was the signing of an exclusive distribution agreement with Diagnos Europe GmbH, a new partner for DIAGNOS to tackle the strategically important DACH countries (Germany, Austria, Switzerland) in the European market and the surrounding countries Poland, Luxembourg and Liechtenstein in order to prepare a successful market entry for the Company’s products and services in Central Europe, a crucial territory for DIAGNOS with a significant market potential in excess of more than 140 million people.

Announced on June 9, 2021, DIAGNOS has signed a multi-year agreement with IRIS The Visual Group Inc. (“IRIS”), creating a world leading platform launch for the deployment and enhancement of AI based tests, screening for vascular changes in the retina for optometry clinics. This very exciting news now means DIAGNOS’s CARA AI platform will be rolled out in a multi-step approach first to the 145 IRIS locations in Quebec, followed by the other store banners across New Look’s network of stores across Canada and Florida over the next year. (Note: The New Look Vision network totals 406 locations operating across North America). The deal has implications beyond diabetic retinopathy as it also includes the potential for additional AI exams that DIAGNOS is developing for hypertension, glaucoma and diabetic macular edema. DIAGNOS will also be receiving some funding from the INVEST-AI program to develop an application for diabetic macular edema using optical coherence tomography (OCT) images. In the news release DIAGNOS stated: “This milestone agreement with IRIS constitutes a major breakthrough for DIAGNOS’ path to continued global commercialization of its technology solutions.”

DIAGNOS’s revenues are forecast to grow rapidly, net profits forecast by 2023

Based on analyst’s forecasts, DIAGNOS is forecast to achieve C$1 million of revenues in 2022 rising to C$7 million by 2023. Due to a forecast strong net profit margin of ~32% in 2023, DIAGNOS is forecast to have a 2023 net profit of C$2.3 million, equating to a 2023 PE ratio of ~21.

DIAGNOS’s CARA AI driven tele-ophthalmology platform studies the retina to detect potential cardiovascular disease in the body

Source: Diagnos Inc. website

Closing remarks

For investors, there is a lot to like about DIAGNOS. A huge global need to better diagnose and screen for cardiovascular disease (especially stroke), ideally at an early stage to achieve positive outcomes. CARA is a cost-effective tool for real-time screening of large volumes of patients and has been cleared for commercialization in the USA, Europe, Canada and multiple other countries. The number of global distributors are growing and this typically leads to revenues and ultimately profits. In particular, the recent news with IRIS The Visual Group, has the potential for rapid North American commercialization.

DIAGNOS trades on a market cap of only C$40 million due to the early stage of commercialization, suitable for investors who are looking for a higher risk and potential high reward stock.




Expanding globally in the AI image based diagnosis sector, Diagnos is actively commercializing their CARA technology

CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. Targeting the early detection of these diseases by using AI to better examine and diagnose patients as early as possible is the focus for Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) (‘Diagnos’).

Diagnos uses an Artificial Intelligence (AI) tool known as CARA (Computer Assisted Retina Analysis) to examine patient’s retinas in the eye for the early detection of diseases such as diabetics, hypertension and other cardiovascular disease. CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software). CARA’s AI image enhancement algorithms make standard retinal images sharper, clearer and easier to read.

Key winning features of CARA:

  • CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras.
  • CARA is a cost-effective tool for screening large numbers of patients in real-time.
  • CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada, licensed by the Saudi FDA, COFEPRIS in Mexico and is CE marking compliant in Europe.

Diagnos’ AI software enhances the ability to detect early-stage cardiovascular disease by viewing the retina of the eye

Source: www.diagnos.ca/

Diagnos has already had their CARA platform in production since mid-February 2020 and will be following with further applications and enhancements for the technology. Diagnos already operates in 16 countries, 131 screening sites, and has 222,034 patients under their care. The Company is fully funded until about mid 2022 and should continue to grow revenues as their CARA platform commercializes further.

Diagnos operates in 16 countries and has 222,034 patients under care

Source: www.diagnos.ca/

The latest news just the past month shows how quickly Diagnos is commercializing. For example:

  • 24 February, 2021 – Exclusive Strategic Partnership Agreement with Labtician Ophthalmics, a leader in Canadian and International eyecare markets. Labtician Ophthalmics has customers across Canada and will introduce and commercialize Diagnos’ AI platform to monitor ocular health and improve patient care in diabetic patients.
  • 2 February, 2021 – Further deployment of Diagnos’ AI based CARA Technology in Saudi Arabia. Dr. Salman Abdullah Al-Mutairi, Executive Director of Enayah Charitable Association stated:

“For almost three years, Enayah has been using DIAGNOS’ AI based CARA platform successfully to screen thousands of diabetic patients for diabetic retinopathy with an early detection test. By using DIAGNOS’ telemedicine solution we have been able to identify patients needing care early so their vision can be saved. As part of our “Combating Blindness” program, we are extremely pleased to extend this service and add it to other tests in our fleet of vans of Mobile Smart Eye Clinics.”

Closing remarks

Diagnos Inc. is in the early days of commercializing their CARA technology having only begun in mid-February 2020, approximately a year ago. This is good news for investors as the company is trading on a market cap of just C$39 million.

I see (no pun intended) exciting times ahead for this company in a potentially huge market.




Drolet Stock Notes on Diagnos: AI driven retina analysis tool for the detection of critical health issues

Mario Drolet, President of MI3 Communications Financières Inc. (MI3), released his Drolet Stock Notes on Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) on October 7, 2020 for exclusive distribution on InvestorIntel. Highlights include:

  • Diagnos has a mission of early detection of critical health issues using its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis).
  • CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.
  • Diagnos signed a contract with Devlyn Grupo, an important optical retailer with over nine hundred stores in Mexico and Guatemala.
  • ADK traded over 21 million shares over the last three months between $0.46 & $0.135
  • Support: S2; $ 0.28   S1; $ 0.33   Resistance:   R1; $0.395    R2; $0.46

About Diagnos

Diagnos is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

PLEASE DO YOUR DUE DILIGENCE

Disclaimer: This Mario Drolet Stock Notes are produced by MI³ Communications Financières is neither an offer to sell, nor the solicitation of an offer to buy any of the securities discussed therein. The information contained is prepared by MI3, emanating from sources deemed to be reliable. MI3 Communications Financières makes no representations or warranties with respect to the accuracy, correctness or completeness of such information. MI³ Communications Financières accepts no liability whatsoever for any loss arising from the use of the information contained therein. Please take note that for compliance purposes, all directors, consultants or employees of MI3 Communications Financières are prohibited from trading the securities of the company and MI3 Communications Financières is a shareholder and do not intend to sell any shares during the distribution of this report.